A recombinant cell bioassay for measurement of overall estrogenic activity of serum: preliminary results in women with breast cancer
-
Sophie Séronie-Vivien
Abstract
The estrogenic status of patients with breast cancer may influence the prognosis and the response to treatment and is currently assessed by immunological measurement of serum estradiol. This does not account for estrogenic or anti-estrogenic activity related to growth factors able to activate the estrogen receptor, to anti-estrogenic drugs or to exogenous supply of estrogen-like compounds. We developed a recombinant bioassay based on a mammary cell line expressing luciferase in an estrogen receptor-dependent way. In a human serum matrix the MELN system was able to detect the transcriptional activity of estradiol, growth factors (epidermal growth factor (EGF), insulin at insulin-like growth factor 1 (IGF-1)-like concentrations), xeno-estrogens (diethylstilbestrol, phytoestrogens) and tamoxifen in a dose-dependent manner. The intra- and inter-assay variations were <6% and ≤15%, respectively, whatever the estradiol concentration; the functional sensitivity was <10 pmol/l equivalents of estradiol. We assessed the overall estrogenic activity of serum (OEAS) in 16 healthy women and in 24 women with advanced breast cancer. The correlation between OEAS and serum log1017-β–estradiol (E2) was good for healthy women (r2 = 0.8568) but poor for patients (r2 = 0.0563). Assessment of the OEAS/E2 ratio as a prognostic and predictive factor would be of interest in clinical prospective trials involving ER+ breast cancer patients.
References
1 Balaguer P, Francois F, Comunale F, Fenet H, Boussioux AM, Pons M, et al. Reporter cell lines to study the estrogenic effects of xenoestrogens. Sci Total Environ 1999; 233:47–56.10.1016/S0048-9697(99)00178-3Search in Google Scholar
2 Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS, McLachlan JA. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol 1993; 7:992–8.Search in Google Scholar
3 Soto AM, Sonnenschein C, Chung KL, Fernandez MF, Olea N, Serrano FO. The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. Environ Health Perspect 1995; 103Suppl 7:113–22.10.1289/ehp.95103s7113Search in Google Scholar
4 DeGregorio M, Wurz G, Emshoff V, Koester S, Minor P, Wiebe V. A bioassay for antiestrogenic activity–potential utility in drug development and monitoring effective in vivo dosing. Breast Cancer Res Treat 1992; 24:35–41.10.1007/BF01832356Search in Google Scholar
5 Legler J, van den Brink CE, Brouwer A, Murk AJ, van der Saag PT, Vethaak AD, et al. Development of a stably transfected estrogen receptor-mediated luciferase reporter gene assay in the human T47D breast cancer cell line. Toxicol Sci 1999; 48:55–66.10.1093/toxsci/48.1.55Search in Google Scholar
6 Rogers JM, Denison MS. Recombinant cell bioassays for endocrine disruptors: development of a stably transfected human ovarian cell line for the detection of estrogenic and anti-estrogenic chemicals. In Vitr Mol Toxicol 2000; 13:67–82.Search in Google Scholar
7 Paris F, Servant N, Terouanne B, Balaguer P, Nicolas JC, Sultan C. A new recombinant cell bioassay for ultrasensitive determination of serum estrogenic bioactivity in children. J Clin Endocrinol Metab 2002; 87:791–7.10.1210/jcem.87.2.8269Search in Google Scholar
8 Klein KO, Baron J, Colli MJ, McDonnell DP, Cutler GB Jr. Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest 1994; 94:2475–80.10.1172/JCI117616Search in Google Scholar
9 Paris F, Servant N, Terouanne B, Sultan C. Evaluation of androgenic bioactivity in human serum by recombinant cell line: preliminary results. Mol Cell Endocrinol 2002; 198:123–9.10.1016/S0303-7207(02)00375-1Search in Google Scholar
10 Raivio T, Palvimo JJ, Dunkel L, Wickman S, Janne OA. Novel assay for determination of androgen bioactivity in human serum. J Clin Endocrinol Metab 2001; 86:1539–44.10.1210/jc.86.4.1539Search in Google Scholar
11 Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003; 9:447S–54S.Search in Google Scholar
12 El Tanani MK, Green CD. Interaction between estradiol and growth factors in the regulation of specific gene expression in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol 1997; 60:269–76.10.1016/S0960-0760(96)00226-9Search in Google Scholar
13 Toomey D, Condron C, Wu QD, Kay E, Harmey J, Broe P, et al. TGF-beta1 is elevated in breast cancer tissue and regulates nitric oxide production from a number of cellular sources during hypoxia re-oxygenation injury. Br J Biomed Sci 2001; 58:177–83.Search in Google Scholar
14 Lissoni P, Malugani F, Bonfanti A, Bucovec R, Secondino S, Brivio F, et al. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeost Agents 2001; 15:140–4.Search in Google Scholar
15 Taniguchi T, Toi M, Inada K, Imazawa T, Yamamoto Y, Tominaga T. Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res 1995; 1:1031–4.Search in Google Scholar
16 Bajetta E, Ferrari L, Celio L, Mariani L, Miceli R, Di Leo A, et al. The aromatase inhibitor letrozole in advanced breast cancer: effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels. J Steroid Biochem Mol Biol 1997; 63:261–7.10.1016/S0960-0760(97)00120-9Search in Google Scholar
17 Chakrabarty S, Huang S, Moskal TL, Fritsche HA Jr. Elevated serum levels of transforming growth factor-alpha in breast cancer patients. Cancer Lett 1994; 79:157–60.10.1016/0304-3835(94)90254-2Search in Google Scholar
18 Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, et al. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000; 88:828–32.10.1002/1097-0215(20001201)88:5<828::AID-IJC22>3.0.CO;2-8Search in Google Scholar
19 Terouanne B, Tahiri B, Georget V, Belon C, Poujol N, Avances C, et al. A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects. Mol Cell Endocrinol 2000; 160:39–49.10.1016/S0303-7207(99)00251-8Search in Google Scholar
20 Gershtein ES, Shcherbakov AM, Alieva SK, Anurova OA, Laktionov KP, Kushlinskii NE. Vascular endothelial growth factor in tumor tissue and blood serum from patients with breast cancer. Bull Exp Biol Med 2003; 135:85–8.10.1023/A:1023414400387Search in Google Scholar
21 Sliutz G, Tempfer C, Obermair A, Dadak C, Kainz C. Serum evaluation of basic FGF in breast cancer patients. Anticancer Res 1995; 15:2675–7.Search in Google Scholar
22 Woodbury RL, Varnum SM, Zangar RC. Elevated HGF levels in sera from breast cancer patients detected using a protein microarray ELISA. J Proteome Res 2002; 1:233–7.10.1021/pr025506qSearch in Google Scholar
23 Chalbos D, Philips A, Galtier F, Rochefort H. Synthetic antiestrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3′,5′-monophosphate in MCF7 cells. Endocrinology 1993; 133:571–6.10.1210/endo.133.2.8344199Search in Google Scholar
24 Andersen HR, Andersson AM, Arnold SF, Autrup H, Barfoed M, Beresford NA, et al. Comparison of short-term estrogenicity tests for identification of hormone-disrupting chemicals. Environ Health Perspect 1999; 107Suppl 1:89–108:89–108.10.1289/ehp.99107s189Search in Google Scholar
© Walter de Gruyter
Articles in the same Issue
- Rapid detection of the factor XIII Val34Leu (163 G→T) polymorphism by real-time PCR using fluorescence resonance energy transfer detection and melting curve analysis
- Changes of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in the serum of patients with autoimmune diseases: association with age and disease activity
- A recombinant cell bioassay for measurement of overall estrogenic activity of serum: preliminary results in women with breast cancer
- N-terminal pro-atrial natriuretic peptide as a biochemical marker of long-term interventional success after radiofrequency catheter ablation of paroxysmal supraventricular tachyarrhythmias
- Preventing in vitro lipoperoxidation in the malondialdehyde-thiobarbituric assay
- Oxidative stress: potential of distinct peroxide determination systems
- Quality assessment in cytogenetic and molecular genetic testing: the experience of the Italian Project on Standardisation and Quality Assurance
- Guidelines for blood smear preparation and staining procedure for setting up an external quality assessment scheme for blood smear interpretation. Part I: control material
- Measurement of serum and plasma osmolality in healthy young humans – influence of time and storage conditions
- High in-hospital mortality of intensive care patients with nucleated red blood cells in blood
- Frequency of –163 C > A and 63 C > G single nucleotide polymorphism of cytochrome P450 1A2 in two African populations
- Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples
- Plasma or serum samples: measurements of cardiac troponin T and of other analytes compared
- Antioxidant capacity of the human pericardial fluid: does gender have a role?
- Comparison of serum digoxin concentration monitoring by fluorescence polarization immunoassay on the TDxFLx® and dry chemistry enzyme immunoassay on the Vitros 950
- Multicenter analytical performance evaluation of the Elecsys® proBNP assay
- Analytical evaluation and reference values of serum amyloid-A on the BN ProSpec
- Reference values of soluble interleukin-2 receptor on the IMMULITE
- Analysis of cystatin C, creatinine, albumin, lipids and lipoprotein concentrations in serum and acidified citrate plasma (Stabilyte™) tubes compared
- Analysis of γ-globulins consisting of hepatitis C-associated cryoglobulins in the blood
- Serum total glutathione-S-transferase in stroke, a preliminary report
- Santorini Biologie Prospective Conference 2004 “From Human Genetic Variations to Prediction of Risks and Responses to the Environment”, Santorini, Greece, September 30–October 4, 2004
Articles in the same Issue
- Rapid detection of the factor XIII Val34Leu (163 G→T) polymorphism by real-time PCR using fluorescence resonance energy transfer detection and melting curve analysis
- Changes of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in the serum of patients with autoimmune diseases: association with age and disease activity
- A recombinant cell bioassay for measurement of overall estrogenic activity of serum: preliminary results in women with breast cancer
- N-terminal pro-atrial natriuretic peptide as a biochemical marker of long-term interventional success after radiofrequency catheter ablation of paroxysmal supraventricular tachyarrhythmias
- Preventing in vitro lipoperoxidation in the malondialdehyde-thiobarbituric assay
- Oxidative stress: potential of distinct peroxide determination systems
- Quality assessment in cytogenetic and molecular genetic testing: the experience of the Italian Project on Standardisation and Quality Assurance
- Guidelines for blood smear preparation and staining procedure for setting up an external quality assessment scheme for blood smear interpretation. Part I: control material
- Measurement of serum and plasma osmolality in healthy young humans – influence of time and storage conditions
- High in-hospital mortality of intensive care patients with nucleated red blood cells in blood
- Frequency of –163 C > A and 63 C > G single nucleotide polymorphism of cytochrome P450 1A2 in two African populations
- Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples
- Plasma or serum samples: measurements of cardiac troponin T and of other analytes compared
- Antioxidant capacity of the human pericardial fluid: does gender have a role?
- Comparison of serum digoxin concentration monitoring by fluorescence polarization immunoassay on the TDxFLx® and dry chemistry enzyme immunoassay on the Vitros 950
- Multicenter analytical performance evaluation of the Elecsys® proBNP assay
- Analytical evaluation and reference values of serum amyloid-A on the BN ProSpec
- Reference values of soluble interleukin-2 receptor on the IMMULITE
- Analysis of cystatin C, creatinine, albumin, lipids and lipoprotein concentrations in serum and acidified citrate plasma (Stabilyte™) tubes compared
- Analysis of γ-globulins consisting of hepatitis C-associated cryoglobulins in the blood
- Serum total glutathione-S-transferase in stroke, a preliminary report
- Santorini Biologie Prospective Conference 2004 “From Human Genetic Variations to Prediction of Risks and Responses to the Environment”, Santorini, Greece, September 30–October 4, 2004
